570 related articles for article (PubMed ID: 32163914)
1. The therapeutic effect of interleukin-22 in high androgen-induced polycystic ovary syndrome.
Qi X; Yun C; Liao B; Qiao J; Pang Y
J Endocrinol; 2020 May; 245(2):281-289. PubMed ID: 32163914
[TBL] [Abstract][Full Text] [Related]
2. Effects of gut microbiota on omega-3-mediated ovary and metabolic benefits in polycystic ovary syndrome mice.
Zhang H; Zheng L; Li C; Jing J; Li Z; Sun S; Xue T; Zhang K; Xue M; Cao C; Ouyang L; Qian Z; Xu R; He Z; Ma R; Chen L; Yao B
J Ovarian Res; 2023 Jul; 16(1):138. PubMed ID: 37443082
[TBL] [Abstract][Full Text] [Related]
3. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
[TBL] [Abstract][Full Text] [Related]
4. The effect of cinnamon on polycystic ovary syndrome in a mouse model.
Dou L; Zheng Y; Li L; Gui X; Chen Y; Yu M; Guo Y
Reprod Biol Endocrinol; 2018 Oct; 16(1):99. PubMed ID: 30340496
[TBL] [Abstract][Full Text] [Related]
5. Effects of dehydroepiandrosterone alone or in combination with a high-fat diet and antibiotic cocktail on the heterogeneous phenotypes of PCOS mouse models by regulating gut microbiota.
Wang X; Gu L; Zhang Y; Xiong C; Peng Y; Ding X
Front Endocrinol (Lausanne); 2022; 13():1030151. PubMed ID: 36619569
[TBL] [Abstract][Full Text] [Related]
6. The use of dehydroepiandrosterone-treated rats is not a good animal model for the study of metabolic abnormalities in polycystic ovary syndrome.
Seow KM; Ting CH; Huang SW; Ho LT; Juan CC
Taiwan J Obstet Gynecol; 2018 Oct; 57(5):696-704. PubMed ID: 30342654
[TBL] [Abstract][Full Text] [Related]
7. The anti-androgenic effect of quercetin on hyperandrogenism and ovarian dysfunction induced in a dehydroepiandrosterone rat model of polycystic ovary syndrome.
Mahmoud AA; Elfiky AM; Abo-Zeid FS
Steroids; 2022 Jan; 177():108936. PubMed ID: 34752810
[TBL] [Abstract][Full Text] [Related]
8. Interlukin-22 improves ovarian function in polycystic ovary syndrome independent of metabolic regulation: a mouse-based experimental study.
Chen W; Liao B; Yun C; Zhao M; Pang Y
J Ovarian Res; 2024 May; 17(1):100. PubMed ID: 38734641
[TBL] [Abstract][Full Text] [Related]
9. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
Rosenfield RL; Ehrmann DA
Endocr Rev; 2016 Oct; 37(5):467-520. PubMed ID: 27459230
[TBL] [Abstract][Full Text] [Related]
10. Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats.
Wu LM; Wang YX; Zhan Y; Liu AH; Wang YX; Shen HF; Wang YF; Wang LY; Tao ZB; Wang YQ
Peptides; 2021 Nov; 145():170624. PubMed ID: 34375684
[TBL] [Abstract][Full Text] [Related]
11. Troxerutin attenuates insulin resistance via pancreatic IL-22/JAK1/STAT3 signaling activation in dihydrotestosterone-induced polycystic ovary syndrome rats.
Gao Z; Wang G; Ma X; Tan H; Zhang C; Yin X; Suo F; Yao R; Yan X
Am J Physiol Endocrinol Metab; 2022 Nov; 323(5):E405-E417. PubMed ID: 36103628
[TBL] [Abstract][Full Text] [Related]
12. Haplosufficient genomic androgen receptor signaling is adequate to protect female mice from induction of polycystic ovary syndrome features by prenatal hyperandrogenization.
Caldwell AS; Eid S; Kay CR; Jimenez M; McMahon AC; Desai R; Allan CM; Smith JT; Handelsman DJ; Walters KA
Endocrinology; 2015 Apr; 156(4):1441-52. PubMed ID: 25643156
[TBL] [Abstract][Full Text] [Related]
13. Modulation of steroidogenesis by vitamin D3 in granulosa cells of the mouse model of polycystic ovarian syndrome.
Bakhshalizadeh S; Amidi F; Alleyassin A; Soleimani M; Shirazi R; Shabani Nashtaei M
Syst Biol Reprod Med; 2017 Jun; 63(3):150-161. PubMed ID: 28345956
[TBL] [Abstract][Full Text] [Related]
14. Total flavonoids extracted from
Zhou Y; Lv L; Liu Q; Song J
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30463907
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome.
Qi X; Yun C; Sun L; Xia J; Wu Q; Wang Y; Wang L; Zhang Y; Liang X; Wang L; Gonzalez FJ; Patterson AD; Liu H; Mu L; Zhou Z; Zhao Y; Li R; Liu P; Zhong C; Pang Y; Jiang C; Qiao J
Nat Med; 2019 Aug; 25(8):1225-1233. PubMed ID: 31332392
[TBL] [Abstract][Full Text] [Related]
16. Myricetin ameliorates polycystic ovary syndrome in mice by brown adipose tissue activation.
Zheng N; Wang C; Li Y; Fu H; Hu T
Reproduction; 2024 Jun; 167(6):. PubMed ID: 38520750
[TBL] [Abstract][Full Text] [Related]
17. Quercetin Decreases Insulin Resistance in a Polycystic Ovary Syndrome Rat Model by Improving Inflammatory Microenvironment.
Wang Z; Zhai D; Zhang D; Bai L; Yao R; Yu J; Cheng W; Yu C
Reprod Sci; 2017 May; 24(5):682-690. PubMed ID: 27634381
[TBL] [Abstract][Full Text] [Related]
18. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
Sanchez-Garrido MA; Tena-Sempere M
Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
[TBL] [Abstract][Full Text] [Related]
19. Polycystic Ovary Syndrome.
Azziz R
Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
[TBL] [Abstract][Full Text] [Related]
20. Hyperandrogenism and insulin resistance-induced fetal loss: evidence for placental mitochondrial abnormalities and elevated reactive oxygen species production in pregnant rats that mimic the clinical features of polycystic ovary syndrome.
Zhang Y; Zhao W; Xu H; Hu M; Guo X; Jia W; Liu G; Li J; Cui P; Lager S; Sferruzzi-Perri AN; Li W; Wu XK; Han Y; Brännström M; Shao LR; Billig H
J Physiol; 2019 Aug; 597(15):3927-3950. PubMed ID: 31206177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
